Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson’s disease
Authors:
- 18 July 2013
- journal article
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 32 (4) , 883-891
Abstract
The monoamine oxidase type-B (MAO-B) inhibitor, selegiline, is often recommended as a first-line treatment for Parkinson's disease (PD) and has been shwon to possess neuroprotective effects. The aim of the present study was to determine whether selegiline increases the levels of the neurotrophic factors (NTFs), glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF), and whether it rescues motor dysfunction and the loss of dopaminergic neurons in mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced lesions. We found that the oral administration of selegiline (1.0 mg/kg/day for 14 days) successfully suppressed the MPTP-induced reduction of nigral dopaminergic neurons and striatal fibers (192.68 and 162.76% of MPTP-exposed animals, respectively; both P<0.001). Moreover, improvements in gait dysfunction were observed after 7 and 14 days of a low dose of selegiline that is reported not to inhibit MAO‑B. Furthermore, there was a significant increase in GDNF and BDNF mRNA (2.10 and 2.75-fold) and protein levels (143.53 and 157.05%) in the selegiline-treated mice compared with the saline-treated MPTP-exposed mice. In addition, the Bax/Bcl-2 gene and protein expression ratios were significantly increased in the MPTP-exposed mice, and this effect was reversed by selegiline. Correlation analysis revealed that gait measurement and GDNF/BDNF levels positively correlated with the number of dopaminergic neurons. These findings demonstrate that selegiline has neurorescue effects that are possibly associated with the induction of NTFs and anti-apoptotic genes.Keywords
This publication has 48 references indexed in Scilit:
- The neuroprotective mechanism of 1‐(R)‐aminoindan, the major metabolite of the anti‐parkinsonian drug rasagilineJournal of Neurochemistry, 2010
- Parkinson's diseaseThe Lancet, 2009
- Multifunctional Neuroprotective Derivatives of Rasagiline as Anti-Alzheimer's Disease DrugsNeurotherapeutics, 2009
- A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristicsMovement Disorders, 2008
- Symptom relief in Parkinson disease by safinamideNeurology, 2006
- Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson’s diseaseAmerican Journal of Health-System Pharmacy, 2006
- Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety2006
- Deprenyl: from chemical synthesis to neuroprotection2006
- Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagilineDrugs of Today, 2005
- Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's diseaseParkinsonism & Related Disorders, 2002